Skip to main content

Plasma and lipoprotein lipid responses to four hypolipid drugs

Lipids volume 19, pages 73–79 (1984)Cite this article

Abstract

The responses of 14 hyperlipidemic subjects to 4 hypolipidemic agents were compared by measureing cholesterol and triglyceride in whole plasma, very low density lipoproteins (VLDL), low density lipoproteins (LDL), and high density lipoproteins (HDL) monthly for 2 months before and 3 months during treatment with each of 4 drugs: clofibrate, 2 g/d; colestipol, 20 g/d; para-aminosalicylic acid-ascorbate (PAS-C), 6–8 g/d; and oxandrolone, 7.5 mg/d. Lipid responses proved to be stable by the first monthly evaluation both off and on each drug. Mean adherence was high and similar for all agents (81–92% of the prescribed dose). Clofibrate was associated with significant decreases in mean plasma cholesterol (−16%, p<.01), plasma triglyceride (−51%, p<.005), VLDL-cholesterol (−61%, p<.005) and VLDL-triglyceride (−61%, P<.005), while HDL cholesterol increased (+20%, p<.01), and the LDL-cholesterol/HDL ratio declined (−24%, p<.05). Colestipol was associated with decreases in mean plasma cholesterol (−15%, p<.01) and LDL-cholesterol (−22%, p<.05), while VLDL-triglyceride increased (+41%, p<.05), and the LDL-cholesterol/HDL-cholesterol ratio declined (−25%, p<.05). PAS-C was associated with decreases in VLDL-cholesterol (−30%, p<.05), and VLDL-triglyceride (−29%, p<.05), while the LDL-cholesterol/HDL-cholesterol ratio remained unchanged. Oxandrolone was associated with increases in mean plasma cholesterol (+7%, p<.05), LDL-cholesterol (+45%, p<.005 [+25% excluding one subject who increased 298%]), and LDL-triglyceride (+24%, p<.01), while decreases occurred in plasma triglyceride (−31%, p<.05), VLDL-cholesterol (−26%, p<.05), VLDL-triglyceride (−42%, p<.005), HDL-cholesterol (−45%, p<.005), and HDL-triglyceride (−43%, p<.01). The mean LDL-cholesterol/HDL-cholesterol ratio increased by 109% (p<.005), reflecting the reciprocal changes in LDL and HDL. Thus, while both clofibrate and colestipol were associated with significant, equivalent reductions in theoretical atherogenic risk, oxandrolone produced a net effect that was not only adverse but 4 times that magnitude, suggesting caution in its long-term use, even for the management of hypertriglyceridemia.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. Cheung, M.C., Albers, J.J., Wahl, P.W., and Hazzard, W.R. (1980) Atherosclerosis 35, 215–228.

    Article  PubMed  CAS  Google Scholar 

  2. Gordon, T., Castelli, W.P., Hjortland, M.C., Kannel, W.B., and Dawber, T.R. (1977) Am. J. Med. 62, 707–714.

    Article  PubMed  CAS  Google Scholar 

  3. Brunzell, J.D., Schrott, H.G., Motulsky, A.G., and Bierman, E.L. (1976) Metabolism 25, 313–320.

    Article  PubMed  CAS  Google Scholar 

  4. Noble, R.P. (1968) J. Lipid Res. 9, 693–700.

    PubMed  CAS  Google Scholar 

  5. Fredrickson, D.S., Morganroth, J., and Levy, R.I. (1975) Ann. Int. Med. 82, 150–157.

    PubMed  CAS  Google Scholar 

  6. Warnick, G.R., Mayfield, C., Albers J.J., and Hazzard, W.R. (1979) Clin. Chem. 25, 279–284.

    PubMed  CAS  Google Scholar 

  7. Lipid Research Clinics Program Manual of Laboratory Operations, (1974) Vol. 1, Lipid and Lipoprotein Analysis, Washington, D.C., US Government Printing Office, DHEW Pub No 75-628.

  8. Winer, B.J. (1962) in Statistical Principles in Experimental Design, McGraw-Hill Book Company, New York, Chapter 7.

    Google Scholar 

  9. Marascuilo, L.A., and McSweeney, M. (1977) in Nonparametric and Distribution-free Methods for the Social Sciences, pp. 176, Brooks/Cole Publishing Co.

  10. Grundy, S.M. (1982) Med. Clin. N. Am. 66, 519–535.

    PubMed  CAS  Google Scholar 

  11. Kane, J.P., and Malloy, M.J. (1982) Med. Clin. N. Am. 66, 537–550.

    PubMed  CAS  Google Scholar 

  12. Albers, J.J., Cheung, M.C., and Hazzard, W.R. (1978) Metab. Clin. Exp. 27, 479.

    PubMed  CAS  Google Scholar 

  13. Breslow, J.L., Spaulding, D.R., Lux, S.E., Levy, R.I., and Less, R.S. (1975) New Eng. J. Med. 293, 900–903.

    Article  PubMed  CAS  Google Scholar 

  14. Goldstein, J.L., Dana, S.E., Brunschede, G.Y., and Brown, M.S. (1975) Proc. Natl. Acad. Sci. U.S.A. 72, 1092–1096.

    Article  PubMed  CAS  Google Scholar 

  15. Brown, M.S., Kovanen, P.T., and Goldstein, J.L. (1981) Science 212, 628–635.

    Article  PubMed  CAS  Google Scholar 

  16. Utermann, G., Vogelberg, K.H., Steinmetz, A., Schoenborn, W., Pruin, N., Jaeschke, M., Hees, M., and Canzler, H. (1979) Clin. Genet. 15, 37–62.

    Article  PubMed  CAS  Google Scholar 

  17. Zannis, V.I., Just, P.W., and Breslow, J.L. (1981) Am. J. Hum. Genet. 3, 11–24.

    Google Scholar 

  18. Havel, R.J. (1982) Med. Clin. N. Am. 66, 441–454.

    PubMed  CAS  Google Scholar 

  19. Hazzard, W.R., Warnick, G.R., Utermann, G., and Albers, J.J. (1981) Metabolism 30, 79–88.

    Article  PubMed  CAS  Google Scholar 

  20. Hazzard, W.R., Albers, J.J., Baron, P., Miller, N., Warnick, G.R., and Lewis, B. (1981) Lancet 1, 298–301.

    Article  PubMed  CAS  Google Scholar 

  21. Wilson, D.E., and Lees, R.S. (1972) J. Clin. Invest. 51, 1051–1057.

    Article  PubMed  CAS  Google Scholar 

  22. Goldstein, J.L., Hazzard, W.R., Schrott, H.G., Bierman, E.L., and Motulsky, A.G. (1973) J. Clin. Invest. 52, 1544–1568.

    PubMed  CAS  Google Scholar 

  23. Boman, H., Hazzard, W.R., Albers, J.J., Cooper, M.N., and Motulsky, A.G. (1975) Am. J. Human Genet. 27, 19A.

    Google Scholar 

  24. Oliver, M.R., Heady, J.A., Morris, J.N., and Cooper, J. (1978) Br. Heart J. 40, 1069–1179.

    Google Scholar 

  25. Lippel, K., Tyroler, H., Eder, H., Gotto, Jr., A., and Vahouny, G. (1981) Arteriosclerosis 1, 406–417.

    PubMed  CAS  Google Scholar 

  26. Brunzell, J.D., and Bierman, E.L. (1982) Med. Clin, N. Am. 66, 455–468.

    CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Northwest Lipid Research Clinic and Departments of Medicine and Biostatistics, University of Washington, 98195, Seattle, WA

    William R. Hazzard, Patricia W. Wahl, Claude Gagne, Deborah Applebaum-Bowden, G. Russell Warnick & John J. Albers

Authors
  1. William R. Hazzard
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patricia W. Wahl
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Claude Gagne
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Deborah Applebaum-Bowden
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. G. Russell Warnick
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. John J. Albers
    View author publications

    You can also search for this author in PubMed Google Scholar

Additional information

William R. Hazzard was an investigator of the Howard Hughes Medical Institute during the course of this study

Claude Gagne was a research fellow of the Medical Research Council of Canada during the course of this study.

John J. Albers is an established investigator of the American Heart Association. of this study

About this article

Cite this article

Hazzard, W.R., Wahl, P.W., Gagne, C. et al. Plasma and lipoprotein lipid responses to four hypolipid drugs. Lipids 19, 73–79 (1984). https://doi.org/10.1007/BF02534494

Download citation

  • Received:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02534494

Keywords

  • High Density Lipoprotein
  • Clofibrate
  • Colestipol
  • Lipid Research Clinic
  • Oxandrolone